JonesResearch analyst Soumit Roy expects shares of Day One Biopharmaceuticals to reach around $17.50-$18 after the FDA approved Ojemda. The stock closed Tuesday up 8% to $16.64. The label is “broad and clean” and matches the firm’s bull case scenario, the analyst tells investors in a research note. JonesResearch keeps a Buy rating on Day One with a $35 price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DAWN:
- Day One’s OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor
- Day One Biopharmaceuticals price target raised to $36 from $32 at JPMorgan
- Day One Biopharmaceuticals trading resumes
- Day One Biopharmaceuticals trading halted, volatility trading pause
- Day One Biopharmaceuticals price target lowered to $33 from $35 at Wedbush
